Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia

Journal of Neurology Neurosurgery and Psychiatry

Volumn 71, Issue 2, 2001, Pages 193-199

  Hilker, R ^a   Schischniaschvili, M ^a   Ghaemi, M ^a   Jacobs, A ^a   Rudolf, J ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Botulinum neurotoxin type A; Focal dystonia; Health related quality of life

Indexed keywords

BOTULINUM TOXIN A;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG COST; DYSTONIA; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; MALE; MENTAL HEALTH; MUSCLE TONE; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

AGED; BOTULINUM TOXIN TYPE A; DYSTONIC DISORDERS; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; TIME FACTORS;

EID: 0034917328     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.71.2.193     Document Type: Article

References (27)

1. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo controlled study. Neurology 1987;27:616-23.
2. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991;324:1186-94.
3. Jankovic J, Schwartz KS. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology 1993;4:834-6.
4. Jahanshahi M, Marsden CD. Body concept, depression and disability in spasmodic torticollis. Behav Neurol 1990;3:117-31.
5. Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990;53:633-9.
6. Guyatt G, Feeny D, Patrick D. Issues in quality of life measurement in clinical trials. Control Clin Trials 1991;12:81-90.
7. The EuroQol Group. EuroQol: a new facility for the measurement of health related quality of life. Health Policy 1990;16:199-208.
8. Garrat AM, Ruta DA, Abdalla MI, et al. The SF-36 healthy survey questionnaire: an outcome measure suitable for routine use within the NHS? BMJ 1993;306:1440-4.
9. Fahn S, Marsden CD, Calne DB. Movement disorders. London: Butterworth, 1987.
10. Tsui JKC, Eisen A, Stoessl AJ, et al. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986;ii:245-7.
11. Fahn S. Assessment of the primary dystonias. In: Munsat TL, ed. Quantification of neurologic deficits. Boston: Butterworth, 1989.
12. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53-72.
13. Ware JE, Snow KK, Kosinski M, et al. Scoring the SF-36. In: SF-36 health survey manual and interpretation guide. Boston, MA: The Health Institute, New England Medical Center, 1993.
14. Kazis L, Anderson J, Meenan R. Effect sizes for interpreting changes in health status. Med Care 1989;27:178-89.
15. Bullinger M. German translation and psychometric testing of the SF-36 health survey: preliminary results from the IQOLA project. International Quality of life assessment. Soc Sci Med 1995;41:359-66.
16. Gudex CM, Hawthorne MR, Butler AG, et al. Effect of dystonia and botulinum toxin treatment on health-related quality of life. Mov Disord 1998;13:941-6.
17. Jahanshahi M, Marsden CD. A longitudinal study of depression, disability and body concept in torticollis. Behav Neurol 1990;3:233-46.
18. Jahanshahi M. Psychosocial factors and depression in torticollis. J Psychosom Res 1991;35:493-507.
19. Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord 1991;6:119-26.
20. Van Zandijcke M. Cervical dystonia (spasmodic torticollis): some aspects of the natural history. Acta Neurol Belg 1995; 95:210-15.
21. Brans JWM, Lindeboom RN, Aramideh M, et al. Long-term effect of botulinum toxin on impairment and functional health in cervical dystonia. Neurology 1998;50:1461-3.
22. Greene P, Kang U, Fahn S, et al. Double-blind, placebo controlled trial of botulinum toxin injection for the treatment of spasmodic torticollis. Neurology 1990;40:1213-18.
23. Jahanshahi M, Marsden CD. Psychological functioning before and after treatment of torticollis with botulinum toxin. Psychol Med 1988;18:925-33.
24. Pirtosek Z, Merello M, Lees AJ. Self-assessment of disability in patients with torticollis. Mov Disord 1992;7(suppl 1):136.
25. Tarsy D. Comparison of clinical rating scales in the treatment of cervical dystonia with botulinum toxin. Mov Disord 1997;12:100-2.
26. Odergren T, Tollbäck A, Borg RPT, et al. Efficacy of botulinum toxin for cervical dystonia. A comparison of the methods for evaluation. Scand J Rehab Med 1994;26:191-5.
27. Lindeboom RL, Brans JWM, Aramideh M, et al. Treatment of cervical dystonia: a comparison of measures for outcome assessment. Mov Disord 1998;13:706-12.